Hidoc Dr | Medical Learning App for Doctors

Today's Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Published Date: 14 Oct 2026

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Published Date: 14 Oct 2026

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Published Date: 14 Oct 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Published Date: 14 Oct 2026

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Published Date: 14 Oct 2026

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Published Date: 14 Oct 2026

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Published Date: 14 Oct 2026

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Published Date: 14 Oct 2026

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Published Date: 14 Oct 2026

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

Published Date: 14 Oct 2026

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

Knowledge Hub

Oncology

Pediatric Cancer Organoid Biobanks and Quality Standards

Comprehensive review of pediatric cancer organoid biobanks, focusing on quality standards and clinical applications.

Oncology

Fertility Preservation Considerations Before Hematologic Cancer Therapy

Comprehensive review of fertility preservation strategies before hematologic cancer therapy for healthcare professionals.

Oncology

Digital Specimen Tracking for Precision Oncology Workflows

Comprehensive review of digital specimen tracking systems in precision oncology workflows for improved diagnostic accuracy and patient safety.

Oncology

Wearable Sensors for Detecting Early Lymphedema Changes

Comprehensive review of wearable sensor technology for early detection of lymphedema in clinical practice.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

Knowledge Hub

Pediatric Cancer Organoid Biobanks and Quality Standards

Fertility Preservation Considerations Before Hematologic Cancer Therapy

Digital Specimen Tracking for Precision Oncology Workflows

Wearable Sensors for Detecting Early Lymphedema Changes

Toxicity Surveillance for Bispecific Cancer Therapies

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

Knowledge Hub

Pediatric Cancer Organoid Biobanks and Quality Standards

Fertility Preservation Considerations Before Hematologic Cancer Therapy

Digital Specimen Tracking for Precision Oncology Workflows

Wearable Sensors for Detecting Early Lymphedema Changes

Toxicity Surveillance for Bispecific Cancer Therapies

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views